MET and breast cancer: The dual MET/ALK inhibitor crizotinib showed a dose-dependent reduction of viability in various breast cancer cell lines after 48 h of treatment, with an IC50 of 5–10 μM18, which is similar to the IC50 obtained in our HGF-stimulated, crizotinib-treated chordoma cells.